Reset Pharmaceuticals

Executive Summary

Reset Pharmaceuticals is a San Diego-based neuro-biotechnology company developing first-in-class, psilocybin-inspired therapies for demoralization syndrome, a condition marked by loss of hope and meaning in patients with life-threatening illnesses such as cancer. Founded in 2018, the company aims to reset neural networks to help patients reconnect with meaning, addressing a significant unmet need in psycho-oncology. While still in early stages with limited public information, Reset Pharmaceuticals occupies a unique niche by targeting a specific psychological condition rather than broad psychiatric indications, which may de-risk development and enable faster regulatory pathways. The company's approach leverages the well-documented effects of psychedelics on neural plasticity and emotional processing, potentially offering a novel therapeutic option for a vulnerable patient population. Given the growing interest in psychedelic medicine and the absence of approved therapies for demoralization syndrome, Reset Pharmaceuticals has a promising yet early-stage opportunity. However, the lack of disclosed funding, valuation, or pipeline milestones introduces uncertainty. The company's success will depend on advancing preclinical or clinical programs, securing partnerships, and navigating regulatory complexities. Overall, Reset Pharmaceuticals represents a high-risk, high-potential opportunity within the psychedelic biotech space.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Clinical Trial for Lead Candidate30% success
• Q1 2027FDA Orphan Drug Designation for Demoralization Syndrome40% success
• Q2 2027Strategic Partnership or Licensing Deal with Larger Pharma25% success